Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,004 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anti-bacterial Agents Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Topical Antibacterial Agents for Prevention of COVID-19

NCT05449392
View directory record Official record
Conditions
COVID-19, SARS-CoV2 Infection
Interventions
Neosporin, Vaseline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

NCT00405704
View directory record Official record
Conditions
Vesicoureteral Reflux, Urinary Tract Infections
Interventions
Trimethoprim-Sulfamethoxazole, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months to 71 Months
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 15, 2026, 1:03 AM EDT
Recruiting Not applicable Interventional

BLOOM: Pragmatic Feasibility Trial

NCT07287332
View directory record Official record
Conditions
Sepsis, Infection
Interventions
Up-front individualized dosing algorithm, Usual Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes

NCT06069206
View directory record Official record
Conditions
Bloodstream Infection, Sepsis Bacterial, MRSA Bacteremia, Vancomycin
Interventions
T2Bacteria® Panel (direct-from-blood testing), Usual Care
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT

NCT04158804
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
procalcitonin
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Torrington, Connecticut • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 15, 2026, 1:03 AM EDT
Not listed Not applicable Interventional

Does a Safety Difference Exist Between IV Push and IV Piggyback Antibiotics?

NCT03360617
View directory record Official record
Conditions
Infection
Interventions
Syringe IV Push over 2-3 minutes, Piggyback over 30 minutes
Device
Lead sponsor
University Medical Center of Southern Nevada
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

NCT03622008
View directory record Official record
Conditions
Antibiotics Causing Adverse Effects in Therapeutic Use
Interventions
FEP-TAZ 4 g, Placebo
Drug · Other
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Improving Safe Antibiotic Prescribing in Telehealth

NCT05138874
View directory record Official record
Conditions
Acute Respiratory Infection, Telehealth
Interventions
Trending Feedback, Benchmark Peer Comparison Feedback, Private Commitment, Public Commitment
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
6,581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

NCT03027609
View directory record Official record
Conditions
Pseudomonas Aeruginosa Pneumonia
Interventions
AR-105, Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Sacramento, California • San Diego, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection

NCT00822692
View directory record Official record
Conditions
Abscess, Methicillin-Resistant Staphylococcus Aureus Infection
Interventions
Trim/ Sulfa DS, placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00423657
View directory record Official record
Conditions
Bacterial Infections
Interventions
ceftaroline, vancomycin plus aztreonam, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
17
States / cities
Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

NCT02731638
View directory record Official record
Conditions
Corneal Ulcer, Fungal Keratitis
Interventions
Intrastromal voriconazole, Natamycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 15, 2026, 1:03 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Not applicable Interventional

ANti-infective Stewardship Using the Wisca Tool in the Electronic Medical Record

NCT03397433
View directory record Official record
Conditions
Bacterial Infections
Interventions
Information Technology physician assist
Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
9,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 15, 2026, 1:03 AM EDT
Recruiting Not applicable Interventional

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

NCT06654752
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
Other
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 18 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Phase 4 Interventional Results available

Topical Antibiotics and Intravitreous Injections

NCT00410891
View directory record Official record
Conditions
Intravitreous, Injections
Interventions
gatifloxacin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 15, 2026, 1:03 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department

NCT00867789
View directory record Official record
Conditions
Abscess
Interventions
Trimethoprim-sulfamethoxazole, Sugar pill
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Months to 17 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 15, 2026, 1:03 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Antibiotics Prescription

NCT06436690
View directory record Official record
Conditions
Antimicrobial Resistance
Interventions
Diagnosis Mandate, Individualized Feedback
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 15, 2026, 1:03 AM EDT
Completed No phase listed Observational

Towards Reducing Resistance and Hematological Toxicity of Linezolid

NCT00177723
View directory record Official record
Conditions
Infection, Adverse Effects
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Oct 15, 2026, 1:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)

NCT03295266
View directory record Official record
Conditions
Hepatic Insufficiency, Antibacterial Agents
Interventions
MK-3866
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

NCT02447172
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Infection
Interventions
Gentamicin Collagen sponge, Placebo
Drug · Other
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 85 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Anniston, Alabama • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota

NCT01414010
View directory record Official record
Conditions
Human Gut Microbiota
Interventions
Trametes versicolor extract, Saccharomyces boulardii, Amoxicillin
Dietary Supplement · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 15, 2026, 1:03 AM EDT
Terminated Phase 4 Interventional Results available

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

NCT05156437
View directory record Official record
Conditions
Endocarditis
Interventions
Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci

NCT02241005
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Vancomycin-Resistant Enterococci
Interventions
Theraworx™ bath wipes, Standard bath wipes
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 15, 2026, 1:03 AM EDT